Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy
Mulligan, G., Lichter, D. I., & Schu, M. (2014). Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood, 123(5), 632-639.
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.